Spago Nanomedical develops nanomedical agents for diagnostics and treatment of cancer. The company´s unique nanoparticles are designed to selectively accumulate in tumors and provide excellent properties for use as contrast agent or radionuclide therapy;
SpagoPix is a gadolinium-free, tumor selective contrast agent for MRI with exceptional signal strength (relaxivity). It has demonstrated proof-of-concept in different tumor models and good safety in regulatory preclinical studies. The first clinical study in cancer patients is currently in preparation.
Tumorad® is a new radionuclide therapy for treatment of solid tumors. It is designed to passively accumulate in tumour tissue to deliver an optimized radiation dose. The project is in preclinical stage.
Spago Nanomedical aim to develop it´s projects into clinical trials and seek strategic licensing partners for further development and commercialization.
Most Recent Vendor Activity